Kusatsu/Shiga Japan – November 9, 2021 – Takara Bio Inc. (Takara Bio), announces today that it has decided jointly with Otsuka Pharmaceutical Co., Ltd. (Otsuka), to terminate agreements on co-development and exclusive marketing of the drug candidates oncolytic virus HF10 (development code: TBI-1401, INN: canerpaturev) and CD19 targeted CAR gene therapies (development code: TBI-1501).
Takara Bio and Otsuka will continue to co-develop NY-ESO-1・siTCR~{TM} gene therapy product (development code: TBI-1301).
1. Reasons for the termination
Oncolytic virus HF10
Both Takara Bio and Otsuka have discussed development plans for pancreatic cancer and other malignancies after the Phase I clinical trial for pancreatic cancer, however, in consideration of the time required for future development and other factors, two companies have decided to terminate the agreement.
CD19-targeted CAR gene therapies
Both companies have been conducting a Phase I/II trial for adult acute lymphoblastic leukemia, however, in consideration of the lengthy period for clinical development and the competitive landscape, the two companies have decided to terminate the agreement.
2. Details of the termination agreement
Under this termination, Takara Bio regains technical, intellectual property and other rights granted by Takara Bio to Otsuka. In addition, in the future Takara Bio will not receive lump-sum payments upon achievement of milestones under this agreement or receive any sales proceeds for clinical trial product sales.
3. Overview of the other party to terminate this agreement
|
[1] Company name |
Otsuka Pharmaceutical Co., Ltd. |
|---|
|
[2] Head office |
2-9, Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-8535, Japan |
|---|
|
[3] URL |
https://www.otsuka.co.jp/en/ |
|---|
4. Schedule
Corporate resolution, date of the termination agreement: November 9, 2021
5. Future Outlook
The impact of the termination of these agreements on the consolidated financial results of the Company for the FY2022 ending March, 2022 will be minor.
